Induction of mania by apomorphine in a depressed parkinsonian patient

Preexisting Bipolar Disorder Influences the Subsequent Phenotype of Parkinson's Disease

Background

Patients with bipolar spectrum disorders (BSDs) exhibit an increased risk of Parkinson's disease (PD).

Objective

The aim is to investigate whether a previous diagnosis of BSDs influences the phenotype of PD.

Methods

Of 2660 PD patients followed for at least 6 years (6–27), 250 (BSD‐PD) had BSDs, 6–20 years before PD diagnosis; 48%–43% had a PD or BSD family history, and 34 carried glucocerebrosidase (GBA) and Parkin (PRKN) mutations. The cohort was split into a subset of 213 BSD‐PD patients, compared with 426 matched PD patients without BSDs, and a subset of 34 BSD‐PD and 79 PD patients carrying GBA or PRKN mutations. Carriers of mutations absent in BSD‐PD patients and of synuclein triplication were excluded. Structured clinical interviews and mood disorder questionnaires assessed BSDs. Linear mixed models evaluated the assessment scales over time. Thirteen BSD‐PD patients underwent subthalamic nucleus deep brain stimulation (STN‐DBS) and were compared with 27 matched STN‐DBS‐treated PD patients.

Results

Compared to PD patients, BSD‐PD showed (1) higher frequency of family history of PD (odds ratio [OR] 3.31; 2.32–4.71) and BSDs (OR 6.20; 4.11–9.35) 5); (2) higher incidence of impulse control disorders (hazard ratio [HR] 5.95, 3.89–9.09); (3) higher frequency of functional disorders occurring before PD therapy (HR, 5.67, 3.95–8.15); (4) earlier occurrence of delusions or mild dementia (HR, 7.70, 5.55–10.69; HR, 1.43, 1.16–1.75); and (5) earlier mortality (1.48; 1.11–1.97). Genetic BSD‐PD subjects exhibited clinical features indistinguishable from nongenetic BSD‐PD subjects. STN‐DBS‐treated BSD‐PD patients showed no improvements in quality of life compared to the control group.

Conclusions

BSDs as a prodrome to PD unfavorably shape their course and are associated with detrimental neuropsychiatric features and treatment outcomes. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society

Psychiatric Conditions in Parkinson Disease: A Comparison With Classical Psychiatric Disorders

Psychiatric conditions often complicate the outcome of patients affected by Parkinson disease (PD), but they differ from classical psychiatric disorders in terms of underlying biological mechanisms, clinical presentation, and treatment response. The purpose of the present review is to illustrate the biological and clinical aspects of psychiatric conditions associated with PD, with particular reference to the differences with respect to classical psychiatric disorders. A careful search of articles on main databases was performed in order to obtain a comprehensive review about the main psychiatric conditions associated with PD. A manual selection of the articles was then performed in order to consider only those articles that concerned with the topic of the review. Psychiatric conditions in patients with PD present substantial differences with respect to classical psychiatric disorders. Their clinical presentation does not align with the symptom profiles represented by Diagnostic and Statistical Manual for Mental Disorders and International Classification of Diseases. Furthermore, psychiatry treatment guidelines are of poor help in managing psychiatric symptoms of patients with PD. Specific diagnostic tools and treatment guidelines are needed to allow early diagnosis and adequate treatment of psychiatric conditions in comorbidity with PD.

Description (reporting the actual words used in written letters) of the neuropsychological and psychopathological modifications produced by dopaminergic treatment in a young patient with Parkinson's disease

Although it is an undeniable fact that dopaminergic therapy has greatly improved the quality of life and prognosis of patients with Parkinson's disease, various and serious adverse events correlated to dopaminergic drugs are not uncommon. Among these, those of neuropsychological and psychopathological nature are of particular importance, being capable of causing an upheaval in the basic personality of the patient. To this regard, the authors report the actual words of a patient himself that are far more convincing that any considerations we may express. In our opinion, the overwhelming impact of dopaminergic treatment on the psychopathological and neuropsychological equilibrium of all parkinsonian patients should unfailingly be carefully evaluated and pondered, particularly in the early onset forms of the disease.

Bipolar Disorder in Neurologic Illness

Patients with neurologic illness frequently develop secondary mood disorders that are broadly categorized as unipolar or bipolar illnesses. Although depressive disorders are more commonly seen in neurologic patients, bipolar illnesses can be as debilitating and more difficult to treat. Distinguishing between primary manias (ie, no known brain injury) and secondary manias (ie, etiologically linked to a disease) is important, because secondary manias may present with different symptoms and require different treatments from primary manias. Aggressive treatment of mania improves quality of life, reduces morbidity and mortality, and may prevent worsening of both psychiatric and neurologic disease. Bipolar disorder associated with neurologic illness typically requires treatment with mood stabilizers such as lithium, divalproex sodium, or carbamazepine. A number of other pharmacologic treatments are emerging, many of them using antiepileptic drugs that may have dual use in neurologic patients. Although psychotherapy in combination with medication improves outcome in bipolar illness, psychotherapy alone is not effective for this condition. Treatment of bipolar disorder, especially in the depressed phase, is complicated, and should be referred to a psychiatrist.

Drug-induced mania

Mania can occur by chance association during drug treatment, particularly in patients predisposed to mood disorder. Single case reports are unreliable, and evidence must be sought from large series of treated patients, particularly those with a matched control group. Drugs with a definite propensity to cause manic symptoms include levodopa, corticosteroids and anabolic-androgenic steroids. Antidepressants of the tricyclic and monoamine oxidase inhibitor classes can induce mania in patients with pre-existing bipolar affective disorder. Drugs which are probably capable of inducing mania, but for which the evidence is less scientifically secure, include other dopaminergic anti-Parkinsonian drugs, thyroxine, iproniazid and isoniazid, sympathomimetic drugs, chloroquine, baclofen, alprazolam, captopril, amphetamine and phencyclidine. Other drugs may induce mania rarely and idiosyncratically. Management involves discontinuation or dosage reduction of the suspected drug, if this is medically possible, and treatment of manic symptoms with antipsychotic drugs or lithium.